Netherton syndrome (NS) is an autosomal recessive disorder characterized by congenital ichthyosis, trichorrhexis invaginata, and severe atopy.1 It presents in the neonatal period, and the ichthyosis develops into serpiginous plaques, bordered by a double-edged scale, termed ichthyosis linearis circumflexa. Hair shaft abnormalities present later in life.1,2 We report a case of NS successfully treated with dupilumab, an interleukin (IL) 4 and IL-13 α antagonist.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Steuer AB, Cohen DE. Treatment of Netherton Syndrome With Dupilumab. JAMA Dermatol. 2020;156(3):350–351. doi:10.1001/jamadermatol.2019.4608
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: